Finch Therapeutics Group Inc
FNCH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.62M
Close$
$-10.92
207% downside
Current Fair Value
207% downsideOvervalued by 207% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $16.62 Million |
|---|---|
| Enterprise Value | $29.57 Million |
| Earnings per Share | $-8.64 |
| Beta | 1.48 |
| Outstanding Shares | 1,605,763 |
Return
| Return on Equity | -99.63% |
|---|---|
| Return on Assets | -31.08% |
| Return on Invested Capital | -48.13% |
Valuation & Multiples
| P/E Ratio | -1.2 |
|---|---|
| PEG | 3.93 |
| Price to Sales | 10.2 |
| Price to Book Ratio | 1.28 |
| Enterprise Value to Revenue | 10.39 |
| Enterprise Value to EBIT | -1.49 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.98 |
| Debt to Equity | 2.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-8.40
Consensus analyst estimateRevenue Estimate
$5.00 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Finch Therapeutics Group Inc
131 employees
CEO: Matthew Blischak
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and ta...